Do We Need Biological Studies for Patient Management?

  • Moosa Qureshi
  • Claire Harrison
Part of the Hematologic Malignancies book series (HEMATOLOGIC)


Our understanding of the pathogenesis of myeloproliferative neoplasms (MPN) has significantly enhanced since the description of the JAK2 V617F mutation as the first robust biological marker of disease (James et al., Nature 434(7037):1144–1148, 2005). Subsequently, further biological landmarks have been achieved in this condition, including descriptions of mutations in other genes, predisposition alleles within the JAK2 gene and others. In the preceding chapter, an update on biological studies has been provided. Here, we review their potential utility in patient management including their role in diagnosis, predicting complications such as thrombosis or haemorrhage and transformation, as well as their function in guiding therapeutic strategies.


Minimal Residual Disease Biological Study JAK2 V617F JAK2 V617F Mutation Allele Burden 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Alchalby H, Badbaran A et al (2010) Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 116(18):3572–3581PubMedCrossRefGoogle Scholar
  2. Alchalby H, Lioznov M et al (2011) Circulating CD34(+) cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT. Bone Marrow Transplant. Epub Feb 2011Google Scholar
  3. Barbui T, Carobbio A et al (2010) Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 115(4):778–782PubMedCrossRefGoogle Scholar
  4. Barbui T, Barosi G et al (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29(6):761–770PubMedCrossRefGoogle Scholar
  5. Barosi G, Bordessoule D et al (2005) Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood 106(8):2849–2853PubMedCrossRefGoogle Scholar
  6. Barosi G, Birgegard G et al (2009) Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 113(20):4829–4833PubMedCrossRefGoogle Scholar
  7. Budde U, Schaefer G et al (1984) Acquired von Willebrand’s disease in the myeloproliferative syndrome. Blood 64(5):981–985PubMedGoogle Scholar
  8. Campbell PJ, Scott LM et al (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366(9501):1945–1953PubMedCrossRefGoogle Scholar
  9. Campbell PJ, Baxter EJ et al (2006) Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 108(10):3548–3555PubMedCrossRefGoogle Scholar
  10. Cervantes F, Dupriez B et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895–2901PubMedCrossRefGoogle Scholar
  11. Cheung B, Radia D et al (2006) The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol 132(2):244–245PubMedCrossRefGoogle Scholar
  12. Dahabreh IJ, Zoi K et al (2009) Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res 33(1):67–73PubMedCrossRefGoogle Scholar
  13. Gangat N, Caramazza D et al (2011) DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29(4):392–397PubMedCrossRefGoogle Scholar
  14. Harrison CN, Campbell PJ et al (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353(1):33–45PubMedCrossRefGoogle Scholar
  15. James C, Ugo V et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434(7037):1144–1148PubMedCrossRefGoogle Scholar
  16. Jones AV, Chase A et al (2009) JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 41(4):446–449PubMedCrossRefGoogle Scholar
  17. Kiladjian JJ, Cassinat B et al (2006) High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 108(6):2037–2040PubMedCrossRefGoogle Scholar
  18. Kroger N, Badbaran A et al (2007) Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 109(3):1316–1321PubMedCrossRefGoogle Scholar
  19. Lengfelder E, Hochhaus A et al (1998) Should a platelet limit of 600 x 10(9)/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br J Haematol 100(1):15–23PubMedCrossRefGoogle Scholar
  20. Mesa RA, Li CY et al (2005) Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 105(3):973–977PubMedCrossRefGoogle Scholar
  21. Murphy S, Iland H et al (1986) Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. Semin Hematol 23(3):177–182PubMedGoogle Scholar
  22. Najean Y, Rain JD (1997) Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. Blood 89(7):2319–2327PubMedGoogle Scholar
  23. Passamonti F, Cervantes F et al (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115(9):1703–1708PubMedCrossRefGoogle Scholar
  24. Patel RK, Lea NC et al (2006) Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 130(7):2031–2038PubMedCrossRefGoogle Scholar
  25. Tefferi A, Barosi G et al (2006) International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 108(5):1497–1503PubMedCrossRefGoogle Scholar
  26. Tefferi A, Lasho TL et al (2008) Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 22(4):756–761PubMedCrossRefGoogle Scholar
  27. Tefferi A, Thiele J et al (2009) The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 115(17):3842–3847PubMedCrossRefGoogle Scholar
  28. Theocharides A, Boissinot M et al (2007) Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110(1):375–379PubMedCrossRefGoogle Scholar
  29. Verstovsek S, Kantarjian H et al (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363(12):1117–1127PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Clinical Research Fellow in HaematologyGuy’s and St Thomas’ NHS Foundation Trust, Guy’s HospitalLondonUK
  2. 2.Guy’s and St Thomas’ NHS Foundation Trust, Guy’s HospitalLondonUK

Personalised recommendations